Trial · NCT01687387

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)

NCT01687387, Phase 2, Completed, Innate Pharma; results first posted 2019-02-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). Trials, record NCT01687387. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01687387

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)
NCT number: NCT01687387
Status: Completed
Phases: Phase 2
Enrollment: 152 participants, actual
Lead sponsor: Innate Pharma
Conditions: Acute Myeloid Leukemia
Interventions: IPH2102 at 0.1 mg/kg, IPH2102 at 1 mg/kg, Placebo (normal saline solution)
First posted: 2012-09-18
Last updated: 2019-02-08
Results first posted: 2019-02-08

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Leukemia-Free Survival	from date of randomization until the date of first documented relapse, assessed up to 48 months
Secondary	Number of Participants With Adverse Events	from the time of patient signing the consent form until 28 days after the last administration, or until the patient's last study visit, up to 24 months	Number of Participants with Adverse Events based on full physical examination each treatment visit and collection of AEs

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Leukemia-Free Survival	from date of randomization until the date of first documented relapse, assessed up to 48 months		MONTHS	MEDIAN
SECONDARY	Number of Participants With Adverse Events	from the time of patient signing the consent form until 28 days after the last administration, or until the patient's last study visit, up to 24 months		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Leukemia-Free Survival	IPH2102 at 1 mg/kg	6.7	95% Confidence Interval 2.9 to 14.8	MONTHS
Leukemia-Free Survival	IPH2102 at 0.1 mg/kg	17.6	95% Confidence Interval 11.2 to 25	MONTHS
Leukemia-Free Survival	Placebo (Normal Saline Solution)	13.9	95% Confidence Interval 7.9 to 27.9	MONTHS
Number of Participants With Adverse Events	IPH2102 at 1 mg/kg	43		Participants
Number of Participants With Adverse Events	IPH2102 at 0.1 mg/kg	49		Participants
Number of Participants With Adverse Events	Placebo (Normal Saline Solution)	47		Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	IPH2102 at 1 mg/kg	51
Overall Study	STARTED	IPH2102 at 0.1 mg/kg	50
Overall Study	STARTED	Placebo (Normal Saline Solution)	51
Overall Study	COMPLETED	IPH2102 at 1 mg/kg	10
Overall Study	COMPLETED	IPH2102 at 0.1 mg/kg	12
Overall Study	COMPLETED	Placebo (Normal Saline Solution)	13
Overall Study	NOT COMPLETED	IPH2102 at 1 mg/kg	41
Overall Study	NOT COMPLETED	IPH2102 at 0.1 mg/kg	38
Overall Study	NOT COMPLETED	Placebo (Normal Saline Solution)	38

Source ClinicalTrials.gov

Adverse events288

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	IPH2102 at 1 mg/kg	3	51	3
other	Anaemia	Blood and lymphatic system disorders	IPH2102 at 0.1 mg/kg	5	50	5
other	Anaemia	Blood and lymphatic system disorders	Placebo (Normal Saline Solution)	2	51	3
other	Neutropenia	Blood and lymphatic system disorders	IPH2102 at 1 mg/kg	4	51	9
other	Neutropenia	Blood and lymphatic system disorders	IPH2102 at 0.1 mg/kg	4	50	5
other	Neutropenia	Blood and lymphatic system disorders	Placebo (Normal Saline Solution)	5	51	11
other	Thrombocytopenia	Blood and lymphatic system disorders	IPH2102 at 1 mg/kg	9	51	9
other	Thrombocytopenia	Blood and lymphatic system disorders	IPH2102 at 0.1 mg/kg	7	50	11
other	Thrombocytopenia	Blood and lymphatic system disorders	Placebo (Normal Saline Solution)	3	51	4
other	Conjunctivitis	Eye disorders	IPH2102 at 1 mg/kg	3	51	3

1 to 10 of 288Source ClinicalTrials.gov

See all 288 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	IPH2102 at 1 mg/kg	32	51
Total, all-cause mortality	IPH2102 at 0.1 mg/kg	26	50
Total, all-cause mortality	Placebo (Normal Saline Solution)	23	51
Total, other adverse events	IPH2102 at 1 mg/kg	38	51
Total, other adverse events	IPH2102 at 0.1 mg/kg	48	50
Total, other adverse events	Placebo (Normal Saline Solution)	43	51
Total, serious adverse events	IPH2102 at 1 mg/kg	12	51
Total, serious adverse events	IPH2102 at 0.1 mg/kg	17	50
Total, serious adverse events	Placebo (Normal Saline Solution)	11	51

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01687387

GET https://conductscience.org/api/trials/v1/NCT01687387/events?page=2

API reference For AI assistants